Mature T-cell and NK-cell non-Hodgkin lymphoma

Researchers are testing a new immune cell therapy called CD5 CAR-T in people with mature T-cell lymphomas that have come back or stopped responding to standard treatment. The trial enrolls about 36 participants, ages 14 to 70, who have few remaining options. Participants receive …

This trial is testing a two-step approach for children, teens, and young adults with advanced T-cell or NK-cell lymphoma or leukemia. First, patients receive a combination of chemotherapy and immunotherapy drugs to shrink the cancer. Then, those who respond go on to receive a ste…

This early-stage trial tests an experimental drug called INCA036873 in about 280 adults with advanced solid tumors or certain blood cancers that have worsened after standard treatments. The main goal is to check safety and find the right dose. Participants receive the drug throug…

This study tests a new drug called AZD3470, alone or with pembrolizumab (Keytruda), in people with certain blood cancers like lymphoma. The goal is to check safety, side effects, and whether the drug shrinks tumors. About 161 adults and teens will take part.

This phase II trial tests whether adding either duvelisib or oral azacitidine to standard chemotherapy improves outcomes for people with certain types of peripheral T-cell lymphoma that have not been treated yet. About 170 participants will receive one of three treatment combinat…

This early-stage trial tests a new gene therapy for certain T-cell lymphomas that have come back or not responded to treatment. The therapy uses a patient's own white blood cells, modified to attack cancer cells that carry a protein called CCR4. Up to 60 adults will receive the m…

This early-stage trial is testing an experimental drug called KK2223 in 72 adults with T-cell lymphoma (a type of blood cancer) that has returned or not responded to prior treatments. The main goals are to check the drug's safety, find the best dose, and see how the body processe…

This trial is testing an experimental drug called LIS1, a specially engineered antibody designed to target and attack cancerous T cells. It is for adults with peripheral T-cell lymphoma (PTCL) that has come back or not responded to previous treatments. The study has two parts: fi…

This study tests an experimental drug called Tulmimetostat (DZR123) in people with advanced solid tumors or lymphomas that have not improved with standard treatments. The drug is taken as a daily pill, either alone or combined with another drug (enzalutamide) for certain prostate…

This study tests two drugs—durvalumab (an immunotherapy) and lenalidomide (a chemotherapy drug)—alone or together in people with T-cell lymphoma that has returned or not responded to prior treatment. The goal is to find the best dose and see how well the combination works. About …

This trial is investigating whether adding an experimental drug called XNW5004 to standard chemotherapy (CHOP or CHOEP) can help people newly diagnosed with peripheral T-cell lymphoma, an aggressive type of non-Hodgkin lymphoma. The study will enroll about 176 adults aged 18 to 7…

This phase 3 trial tests whether adding either belinostat or pralatrexate to standard chemotherapy helps people with newly diagnosed peripheral T-cell lymphoma live longer without their cancer getting worse. About 504 participants will be randomly assigned to one of three treatme…

This early-phase trial tests a new approach for people with certain lymphomas that have come back or not responded to treatment. Researchers take immune cells from healthy donors, modify them to recognize and attack CD30-positive cancer cells, and add a molecule (C7R) to boost th…

This trial investigates whether combining two FDA-approved drugs, duvelisib and venetoclax, can safely and effectively treat peripheral T-cell lymphoma that has returned or stopped responding to prior therapies. The study enrolls adults who have tried at least two previous treatm…

This early-stage study tests an experimental drug called ELA026 in adults with T/NK cell blood cancers that have come back or not responded to prior treatments. The main goals are to check the drug's safety and find the right dose. About 84 participants will be enrolled across mu…

This phase II trial tests the drug chidamide in people with peripheral T-cell lymphoma that has come back or stopped responding to treatment. The study aims to see if chidamide can shrink tumors and how safe it is. Participants take chidamide twice a week, and doctors monitor the…

This early-phase trial tests a genetically modified virus (VSV-hIFNβ-NIS) combined with an immunotherapy drug (cemiplimab) in adults with relapsed or refractory T-cell lymphoma. The virus is designed to kill cancer cells while leaving healthy cells alone, and the immunotherapy he…

This program provides single-patient access to tipifarnib, an experimental drug, for adults with HRAS mutations or peripheral T-cell lymphoma (PTCL) who have exhausted standard treatments and cannot join other clinical trials. The goal is to offer a potential treatment when no sa…

This study tests a new drug called CCS1477 (inobrodib) in people with advanced blood cancers like leukemia, lymphoma, and myeloma that have not responded to standard treatments. The drug is given as an oral capsule, either alone or combined with other cancer medicines. The goal i…

This study tests two drugs, tislelizumab and zeprumetostat, together in people with a rare type of lymphoma that has come back or not responded to treatment. About 107 adults will take part to see if the combination is safe and shrinks tumors. The goal is to control the cancer, n…

This early-phase trial tests a genetically modified virus (VSV-IFNβ-NIS) alone or with chemotherapy and immunotherapy drugs in people with blood cancers like multiple myeloma, acute myeloid leukemia, and lymphomas that have returned or not responded to treatment. The virus is des…

This phase 2 trial is testing whether combining two drugs—pembrolizumab (Keytruda) and brentuximab vedotin (Adcetris)—can shrink tumors in people with a type of T-cell lymphoma that has returned or not responded to at least one prior treatment. The study enrolls adults with CD30-…

This Phase 3 trial tests a new drug, golidocitinib, against standard treatments for adults with relapsed or refractory peripheral T-cell lymphoma, a rare blood cancer. About 218 participants worldwide will receive either golidocitinib pills or a doctor-chosen drug. The goal is to…

This phase 1 trial is testing whether adding the drug ruxolitinib to standard CHOP chemotherapy is safe and effective for people with untreated nodal T-follicular helper (TFH) cell lymphoma, a rare type of non-Hodgkin lymphoma. About 20 adults will receive the combination to find…

This observational study tracks 100 adults in Spain with CD30-positive peripheral T-cell lymphoma who received brentuximab vedotin plus CHP as their first treatment. Researchers will review medical records to see how long patients live without their cancer getting worse, how well…

This study tests a combination of three drugs (azacitidine, chidamide, and a PD-1 inhibitor) in 30 adults with peripheral T-cell lymphoma that has not responded to or has returned after prior treatment. The goal is to see if the combo can shrink tumors and delay cancer growth. Pa…

This phase 3 trial compares two drug combinations given after a stem cell transplant to prevent graft-versus-host disease (GVHD), a serious complication where donor cells attack the patient's body. The study will enroll 572 adults with blood cancers like leukemia or myelodysplasi…

This study tests whether combining two drugs, duvelisib and chidamide, can safely control peripheral T-cell lymphoma in people who are newly diagnosed. About 36 adults aged 18 to 70 will receive the combination and be monitored for side effects and how well the cancer responds. T…

This study tests a new type of CAR-T cell therapy that targets a protein called CD5 on cancer cells. It is for people with T-cell acute lymphoblastic leukemia or T-cell lymphoma that has come back or not responded to treatment. The trial has two phases: first, finding the safest …

This phase 2 trial is testing whether combining an immunotherapy drug (anti-PD-1) with two chemotherapy-like drugs (lenalidomide and azacitidine) can shrink tumors in people with peripheral T-cell lymphoma that has come back or not responded to prior treatment. About 31 participa…

This study tests a combination of two drugs, GW5282 and golidocitinib, for people with T-cell lymphoma. The first part finds the safest dose; the second part compares the combo to standard chemotherapy. About 165 adults with newly diagnosed or relapsed disease will take part. The…

This phase II trial is testing whether the drug ruxolitinib, taken as a daily pill after a stem cell transplant, can help prevent T-cell lymphoma from coming back and reduce the risk of graft-versus-host disease (GVHD). The study will enroll 44 adults with various T-cell lymphoma…

This study tests a new type of CAR-T cell therapy that targets two different markers on cancer cells at once, aiming to prevent the cancer from escaping treatment. It is for adults with several types of blood cancers that have come back or not responded to standard treatments. Pa…

This phase 3 trial tests a new oral drug, soquelitinib, against standard single-agent chemotherapy in 150 adults with relapsed or refractory peripheral T-cell lymphoma. The study aims to see if soquelitinib can delay cancer progression better than current options. Participants ar…

This phase 3 trial tests the drug duvelisib against two standard chemotherapy drugs (gemcitabine or bendamustine) in 124 people with a rare type of lymphoma (nodal T cell lymphoma with TFH phenotype) that has returned or not responded to prior treatment. The main goal is to see i…

This study tests whether combining two drugs—sintilimab and chidamide—can help people with a rare type of lymphoma (peripheral T-cell lymphoma) that has returned or not responded to prior treatments. About 51 adults aged 18 to 75 will receive the drug combination. The goal is to …

This study tests whether the drug golidocitinib can help keep peripheral T-cell lymphoma (a rare blood cancer) from coming back after initial chemotherapy. About 136 adults who had a good response to first treatment but cannot or choose not to have a stem cell transplant will tak…

This phase 2 trial tests two oral drugs, SHR-0302 and SHR-2554, in about 25 people with peripheral T-cell lymphoma that has come back or not responded to prior treatment. The drugs work by blocking specific proteins that help cancer grow. The study aims to see if the combination …

This early-stage trial is testing a new treatment for people with relapsed or refractory peripheral T-cell lymphoma, a rare and aggressive blood cancer. The therapy uses immune cells (NK cells) from donated umbilical cord blood that are genetically modified to recognize and attac…

This study is for people with peripheral T-cell lymphoma whose cancer did not shrink or got worse after standard first treatment. It compares a stem cell transplant from a donor to other rescue treatments. The goal is to see which approach helps people live longer and control the…

This program offers early access to the investigational drug selinexor for people with certain advanced cancers, such as multiple myeloma, lymphoma, sarcoma, and others, who have no other treatment options. Patients must not qualify for any ongoing clinical trial and must have ex…

This Phase 3 trial tests whether the drug golidocitinib can help people with peripheral T-cell lymphoma (PTCL) stay in remission longer after their first round of chemotherapy. About 136 patients who responded to chemo will receive either golidocitinib or a placebo pill every oth…

This phase 2 trial is testing whether adding the targeted drug golidocitinib to standard chemotherapy (CHOP) can better control newly diagnosed peripheral T cell lymphoma, a rare and aggressive blood cancer. About 30 adults will receive the combination, and researchers will monit…

This study is testing three oral drugs—roginolisib, golcadomide, and azacitidine—alone or in combination for people with peripheral T-cell lymphoma that has come back or not responded to treatment. The trial has two phases: Phase 1 finds safe doses, and Phase 2 checks if the drug…

This study tests whether combining two drugs, cidabenamine and azacitidine, can stop high-risk peripheral T-cell lymphoma from progressing after a stem cell transplant. About 40 adults aged 18 to 70 will receive the drug combo as maintenance therapy. The goal is to see if it impr…

This study tests an experimental oral drug called HH2853 in about 100 people with peripheral T-cell lymphoma that has come back or not responded to prior treatments. The drug works by blocking certain proteins that help cancer cells grow. The goal is to see if it can shrink tumor…

This study tests an experimental drug called HH2853 in people with certain types of blood cancer (non-Hodgkin lymphoma) or advanced solid tumors that have come back or stopped responding to treatment. The drug is taken as a tablet twice a day. The main goals are to find the safes…

This early-stage study tests a new oral drug, AXT-1003, in 78 people with advanced non-Hodgkin lymphoma or solid tumors that have not responded to standard treatments. The main goal is to check safety and find the right dose. Researchers will also look for signs that the drug shr…

This study tests a combination of three drugs (zeprumetostat, azacitidine, and mitoxantrone hydrochloride liposome) in about 26 adults with peripheral T-cell lymphoma that has come back or not responded to prior treatment. The goal is to see if this mix can shrink tumors and help…

This study looks at whether a stem cell transplant (using a patient's own cells) after successful first treatment can help control peripheral T-cell lymphoma. About 160 people will either get the transplant or just be monitored. The goal is to see if the transplant delays the can…

This study tests if a combination of two drugs (romidepsin and oral azacytidine) works better than standard single drugs for people with peripheral T-cell lymphoma (PTCL) that has returned or not responded to prior therapy. About 50 adults will be randomly assigned to either the …

This Phase 3 trial tests whether the experimental drug XNW5004 can help people with relapsed or refractory peripheral T-cell lymphoma, a rare and aggressive blood cancer. About 120 participants will receive either XNW5004 or the existing drug chidamide. The main goal is to see if…

This phase 3 trial compares a new drug called SHR2554 to an existing drug, chidamide, in 130 people with a rare type of lymphoma (PTCL) that has come back or not responded to at least one prior treatment. The main goal is to see if SHR2554 can delay cancer growth better than chid…

This study tests whether combining the drug golidocitinib with either mitoxantrone liposome or chidamide can safely shrink tumors in people with peripheral T-cell lymphoma that has returned or not responded to prior therapy. About 101 adults will receive one of the combinations. …

This study compares two types of stem cell transplants for people with peripheral T-cell lymphoma whose cancer only partially responded to first treatment. One group receives their own stem cells, the other receives cells from a matched donor. The goal is to see which approach le…

This phase II trial is testing whether adding the JAK inhibitor ruxolitinib to the immunotherapy drug pembrolizumab is safe and effective for people with relapsed or refractory Hodgkin and non-Hodgkin lymphomas. The study will enroll 53 participants with specific lymphoma subtype…

This study tests a new combination of two targeted drugs (linperlisib and chidamide) against standard chemotherapy for people with a rare type of blood cancer called peripheral T-cell lymphoma. The goal is to see if the new combo works better at shrinking tumors and controlling t…

This early-phase trial tests whether a personalized immune cell therapy called anti-EBV TCR-T cells is safe for people with relapsed or refractory EBV-positive lymphoma who have a specific genetic marker (HLA-A11:01). The treatment involves taking a patient's own T cells, enginee…

This study tests a new treatment called MB-105 for people with a type of blood cancer called T-cell lymphoma that has come back or not responded to standard treatments. MB-105 is made from the patient's own immune cells, which are modified to better recognize and attack cancer ce…

This Phase 2 trial tests a combination of the drug linperlisib plus three older drugs (cyclophosphamide, prednisone, and thalidomide) in 180 adults with non-Hodgkin lymphoma that has returned or not responded to treatment. The goal is to see how many patients achieve a complete o…

This study tests a new approach for people with peripheral T-cell lymphoma that has come back or not responded to standard treatments. Researchers take a patient's own immune T-cells, modify them in the lab to recognize and attack cancer cells carrying the CD30 protein, and infus…

This early-stage trial is testing a new form of fenretinide (a vitamin A-like drug) given by IV for people with T-cell non-Hodgkin lymphoma that has come back or stopped responding to treatment. The study has two parts: first, finding the safest dose in small groups of patients, …

This phase 3 trial is testing whether adding the targeted drug tucidinostat to standard CHOP chemotherapy helps people with a rare form of lymphoma called peripheral T-cell lymphoma with TFH phenotype. About 224 newly diagnosed adults will receive either tucidinostat or a placebo…

This phase 2 trial tests whether combining pembrolizumab (an immunotherapy) with olaparib (a targeted drug) can shrink tumors in people with peripheral T-cell lymphoma that has come back or not responded to treatment. About 24 adults in Singapore will receive the drugs intravenou…

This pilot study tests a small microdevice that is temporarily placed inside a skin lesion to release up to 19 different cancer drugs at once. The goal is to see if the device can safely and effectively show which drugs kill the cancer cells in that specific patient. The study in…

This study gathers blood and leftover tissue samples from 200 people newly diagnosed with aggressive non-Hodgkin lymphoma, including types like diffuse large B-cell lymphoma and T-cell lymphoma. The samples are used to develop and validate blood-based tests that could monitor can…

This study looks at how the immune system of people with lymphoma responds to flu and COVID vaccines. Researchers will measure antibody levels and immune cells over time in 200 participants with different types of lymphoma. The goal is to understand how lymphoma and its treatment…

This study looks at how the body processes venetoclax when the tablet is crushed and mixed into a liquid. It includes 30 children and young adults with blood cancers who already take venetoclax this way. The goal is to measure drug levels in the blood and spinal fluid to ensure t…

This study will follow 3000 people in China with peripheral T-cell lymphoma, a rare and aggressive blood cancer. Researchers will track which treatments patients actually receive and how they fare, aiming to build better prediction tools and understand why some patients relapse. …